Acurx Pharmaceuticals
ACXP
25 hedge funds and large institutions have $2.71M invested in Acurx Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
39% more call options, than puts
Call options by funds: $78K | Put options by funds: $56K
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.05% less ownership
Funds ownership: 0.43% → 0.38% (-0.05%)
4% less funds holding
Funds holding: 26 → 25 (-1)
11% less capital invested
Capital invested by funds: $3.05M → $2.71M (-$342K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$44K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$30K |
| 3 |
LPL Financial
San Diego,
California
|
+$29.7K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$22.2K |
| 5 |
BlackRock
New York
|
+$19.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$92.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$91.7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$31.9K |
| 4 |
Two Sigma Investments
New York
|
-$31.8K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$18.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
XT
26
XTX Topco
George Town,
Cayman Islands
| – | -$31.9K | -652 | Closed |
|
|
27
Two Sigma Investments
New York
| – | -$31.8K | -649 | Closed |
|
28
Wells Fargo
San Francisco,
California
| – | -$213 | -4 | Closed |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$220 | +5 | +250% |
|
ACXP Hedge Fund Activity: Q2 2024 in Review
25 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q2 2024, worth a combined $2.71M — down 11% from $3.05M a quarter earlier.
Fund positioning in ACXP was balanced in Q2 2024: 4 funds opened new positions, 4 closed out, 9 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $44K. The largest seller was Osaic Holdings, cutting an estimated $92.4K.
- 25 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q2 2024, down from 26 in Q1 2024.
- Funds reported $2.71M of Acurx Pharmaceuticals stock for Q2 2024, down 11% quarter-over-quarter.
- 4 funds opened new Acurx Pharmaceuticals positions in Q2 2024 and 4 closed out, a net change of 0 holders.
- The largest Acurx Pharmaceuticals buyer in Q2 2024 was Morgan Stanley, an estimated $44K added.
- The largest Acurx Pharmaceuticals seller in Q2 2024 was Osaic Holdings, an estimated $92.4K sold.
Based on aggregated 13F filings for Q2 2024.